Patent ID: 8309061

Claim:
A formulation for the treatment of symptoms associated with rhinosinusitis in a mammal suffering from rhinosinusitis, the formulation comprising an aqueous suspension comprising: (a) about 10 mcg to about 2000 mcg of an anti-inflammatory agent, the anti-inflammatory agent comprises suspended solid particles of fluticasone or pharmaceutically acceptable salt thereof, said suspended solid particles of fluticasone comprise the following particle size distribution profile: i. about 10% of the anti-inflammatory particles has an average particle size of less than 0.40 microns; ii. about 25% of the anti-inflammatory particles have an average particle size of less than 0.8 microns; iii. about 50% of the anti-inflammatory particles have an average particle size of less than 1.5 microns; iv. about 75% of the anti-inflammatory particles have an average particle size of less than 3.0 microns; and v. about 90% of the anti-inflammatory particles have an average particle size distribution of less than 5.3 microns; and (b) an antifungal agent, wherein the formulation is suitable for administration by the intranasal route of the mammal; wherein the formulation is sterile and free of benzalkonium chloride.